Matt O'Brien
Stock Analyst at Piper Sandler
(2.21)
# 2,804
Out of 5,139 analysts
195
Total ratings
43.29%
Success rate
-4.6%
Average return
Main Sectors:
Stocks Rated by Matt O'Brien
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GMED Globus Medical | Reiterates: Overweight | $90 → $115 | $93.47 | +23.03% | 13 | Jan 8, 2026 | |
| KMTS Kestra Medical Technologies | Maintains: Overweight | $27 → $30 | $22.85 | +31.29% | 2 | Dec 12, 2025 | |
| TELA TELA Bio | Reiterates: Neutral | $2 → $1.25 | $1.02 | +22.55% | 7 | Nov 14, 2025 | |
| SI Shoulder Innovations | Reiterates: Overweight | $18 | $13.96 | +28.94% | 2 | Nov 12, 2025 | |
| CNMD CONMED | Maintains: Overweight | $68 → $55 | $41.57 | +32.31% | 14 | Nov 6, 2025 | |
| PRCT PROCEPT BioRobotics | Reiterates: Overweight | $55 → $50 | $30.38 | +64.58% | 5 | Nov 5, 2025 | |
| DXCM DexCom | Maintains: Overweight | $100 → $75 | $69.54 | +7.85% | 13 | Oct 31, 2025 | |
| ATEC Alphatec Holdings | Reiterates: Overweight | $20 → $25 | $17.74 | +40.92% | 4 | Oct 31, 2025 | |
| TMDX TransMedics Group | Maintains: Overweight | $145 → $140 | $143.37 | -2.35% | 13 | Oct 30, 2025 | |
| BBNX Beta Bionics | Reiterates: Overweight | $26 → $32 | $18.50 | +72.97% | 2 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $155 → $82 | $85.78 | -4.41% | 3 | Oct 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $22 | $18.35 | +19.89% | 3 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $18 | $12.57 | +43.20% | 1 | Aug 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $30 → $14 | $20.16 | -30.56% | 9 | Aug 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $12 | $5.21 | +130.33% | 9 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $180 → $165 | $120.24 | +37.23% | 10 | Apr 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $5.5 → $3.5 | $6.47 | -45.90% | 7 | Mar 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $255 → $140 | $103.00 | +35.92% | 5 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $285 → $310 | $287.70 | +7.75% | 8 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $250 → $330 | $350.78 | -5.92% | 13 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $50 | $39.06 | +28.01% | 3 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $16 | $20.97 | -23.70% | 7 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $95 → $115 | $88.07 | +30.58% | 3 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $9 → $12 | $3.90 | +207.69% | 7 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $380 → $420 | $363.78 | +15.45% | 12 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $90 | $96.76 | -6.99% | 9 | Aug 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $25 | $17.00 | +47.06% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $3.5 → $3 | $1.11 | +170.27% | 2 | Nov 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $4 → $4.5 | $3.99 | +12.78% | 2 | Aug 11, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $87.31 | - | 2 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $15 | $4.22 | +255.45% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $109 | $82.37 | +32.03% | 1 | Feb 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $100 → $80 | $20.11 | +297.81% | 1 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.51 | +117.79% | 1 | Jun 24, 2020 |
Globus Medical
Jan 8, 2026
Reiterates: Overweight
Price Target: $90 → $115
Current: $93.47
Upside: +23.03%
Kestra Medical Technologies
Dec 12, 2025
Maintains: Overweight
Price Target: $27 → $30
Current: $22.85
Upside: +31.29%
TELA Bio
Nov 14, 2025
Reiterates: Neutral
Price Target: $2 → $1.25
Current: $1.02
Upside: +22.55%
Shoulder Innovations
Nov 12, 2025
Reiterates: Overweight
Price Target: $18
Current: $13.96
Upside: +28.94%
CONMED
Nov 6, 2025
Maintains: Overweight
Price Target: $68 → $55
Current: $41.57
Upside: +32.31%
PROCEPT BioRobotics
Nov 5, 2025
Reiterates: Overweight
Price Target: $55 → $50
Current: $30.38
Upside: +64.58%
DexCom
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $75
Current: $69.54
Upside: +7.85%
Alphatec Holdings
Oct 31, 2025
Reiterates: Overweight
Price Target: $20 → $25
Current: $17.74
Upside: +40.92%
TransMedics Group
Oct 30, 2025
Maintains: Overweight
Price Target: $145 → $140
Current: $143.37
Upside: -2.35%
Beta Bionics
Oct 29, 2025
Reiterates: Overweight
Price Target: $26 → $32
Current: $18.50
Upside: +72.97%
Oct 24, 2025
Maintains: Overweight
Price Target: $155 → $82
Current: $85.78
Upside: -4.41%
Oct 10, 2025
Maintains: Overweight
Price Target: $30 → $22
Current: $18.35
Upside: +19.89%
Aug 18, 2025
Initiates: Overweight
Price Target: $18
Current: $12.57
Upside: +43.20%
Aug 7, 2025
Downgrades: Neutral
Price Target: $30 → $14
Current: $20.16
Upside: -30.56%
May 9, 2025
Maintains: Overweight
Price Target: $20 → $12
Current: $5.21
Upside: +130.33%
Apr 15, 2025
Maintains: Overweight
Price Target: $180 → $165
Current: $120.24
Upside: +37.23%
Mar 6, 2025
Maintains: Neutral
Price Target: $5.5 → $3.5
Current: $6.47
Upside: -45.90%
Feb 28, 2025
Downgrades: Neutral
Price Target: $255 → $140
Current: $103.00
Upside: +35.92%
Feb 21, 2025
Maintains: Overweight
Price Target: $285 → $310
Current: $287.70
Upside: +7.75%
Feb 19, 2025
Reiterates: Overweight
Price Target: $250 → $330
Current: $350.78
Upside: -5.92%
Feb 13, 2025
Maintains: Overweight
Price Target: $40 → $50
Current: $39.06
Upside: +28.01%
Feb 12, 2025
Maintains: Neutral
Price Target: $40 → $16
Current: $20.97
Upside: -23.70%
Feb 3, 2025
Maintains: Overweight
Price Target: $95 → $115
Current: $88.07
Upside: +30.58%
Nov 8, 2024
Reiterates: Neutral
Price Target: $9 → $12
Current: $3.90
Upside: +207.69%
Oct 30, 2024
Reiterates: Overweight
Price Target: $380 → $420
Current: $363.78
Upside: +15.45%
Aug 21, 2024
Maintains: Neutral
Price Target: $85 → $90
Current: $96.76
Upside: -6.99%
Mar 28, 2024
Initiates: Overweight
Price Target: $25
Current: $17.00
Upside: +47.06%
Nov 10, 2023
Maintains: Neutral
Price Target: $3.5 → $3
Current: $1.11
Upside: +170.27%
Aug 11, 2023
Maintains: Overweight
Price Target: $4 → $4.5
Current: $3.99
Upside: +12.78%
Mar 10, 2023
Upgrades: Overweight
Price Target: n/a
Current: $87.31
Upside: -
Feb 24, 2023
Initiates: Overweight
Price Target: $15
Current: $4.22
Upside: +255.45%
Feb 11, 2021
Maintains: Overweight
Price Target: $93 → $109
Current: $82.37
Upside: +32.03%
Jan 29, 2021
Downgrades: Neutral
Price Target: $100 → $80
Current: $20.11
Upside: +297.81%
Jun 24, 2020
Initiates: Overweight
Price Target: $12
Current: $5.51
Upside: +117.79%